Literature DB >> 24232751

3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration.

Rebecca L Hartman1,2, Nathalie A Desrosiers1,2, Allan J Barnes1, Keming Yun1,3, Karl B Scheidweiler1, Erin A Kolbrich-Spargo4, David A Gorelick1,5, Robert S Goodwin6, Marilyn A Huestis7.   

Abstract

3,4-Methylenedioxymethamphetamine (MDMA) is an illicit phenethylamine ingested for entactogenic and euphoric effects. Although blood is more commonly submitted for forensic analysis, previous human MDMA pharmacokinetics research focused on plasma data; no direct blood-plasma comparisons were drawn. Blood and plasma specimens from 50 healthy adult volunteers (33 males, 17 females, 36 African-American) who ingested recreational 1.0 and 1.6 mg/kg MDMA doses were quantified for MDMA and metabolites 4-hydroxy-3-methoxymethamphetamine (HMMA), 3,4-methylenedioxyamphetamine (MDA), and 4-hydroxy-3-methoxyamphetamine (HMA) by two-dimensional gas chromatography-mass spectrometry. Specimens were collected up to 3 h post-dose and evaluated for maximum concentration (C max), first detection time (t first), time of C max (t max), and 3-h area under the curve (AUC0-3 h); as well as blood metabolite ratios and blood/plasma ratios. Median blood MDMA and MDA C max were significantly greater (p < 0.0005) than in plasma, but HMMA was significantly less (p < 0.0005). HMA was detected in few blood specimens, at low concentrations. Nonlinear pharmacokinetics were not observed for MDMA or MDA in this absorptive phase, but HMMA C max and AUC0-3 h were similar for both doses despite the 1.6-fold dose difference. Blood MDA/MDMA and MDA/HMMA significantly increased (p < 0.0001) over the 3-h time course, and HMMA/MDMA significantly decreased (p < 0.0001). Blood MDMA C max was significantly greater in females (p = 0.010) after the low dose only. Low-dose HMMA AUC0-3 h was significantly decreased in females' blood and plasma (p = 0.027) and in African-Americans' plasma (p = 0.035). These data provide valuable insight into MDMA blood-plasma relationships for forensic interpretation and evidence of sex- and race-based differential metabolism and risk profiles. Figure Median (interquartile range) blood/plasma 3,4-methylenedioxymethamphetamine (MDMA) (a), 4-hydroxy-3-methoxymethamphetamine (HMMA) (b), and 3,4-methylenedioxyamphetamine (MDA) (c) ratios for 3 h after controlled MDMA administration. Changes over time were significant after the 1.6 mg/kg dose for HMMA and MDA (p = 0.013 and p = 0.021), but not for MDMA. No changes over time were significant after the 1.0 mg/kg dose. Note: y-axes do not begin at 0. *p  < 0.05 (low vs. high).

Entities:  

Keywords:  Blood; Ecstasy; MDMA; Metabolites; Pharmacokinetics; Plasma

Year:  2013        PMID: 24232751      PMCID: PMC4492916          DOI: 10.1007/s00216-013-7468-y

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  33 in total

1.  Determination of the designer drugs 3, 4-methylenedioxymethamphetamine, 3,4-methylenedioxyethylamphetamine, and 3,4-methylenedioxyamphetamine with HPLC and fluorescence detection in whole blood, serum, vitreous humor, and urine.

Authors:  K M Clauwaert; J F Van Bocxlaer; E A De Letter; S Van Calenbergh; W E Lambert; A P De Leenheer
Journal:  Clin Chem       Date:  2000-12       Impact factor: 8.327

2.  Usefulness of saliva for measurement of 3,4-methylenedioxymethamphetamine and its metabolites: correlation with plasma drug concentrations and effect of salivary pH.

Authors:  M Navarro; S Pichini; M Farré; J Ortuño; P N Roset; J Segura; R de la Torre
Journal:  Clin Chem       Date:  2001-10       Impact factor: 8.327

3.  High performance liquid chromatographic assays of the illicit designer drug "Ecstasy", a modified amphetamine, with applications to stability, partitioning and plasma protein binding.

Authors:  E R Garrett; K Seyda; P Marroum
Journal:  Acta Pharm Nord       Date:  1991

4.  Quantitation of amphetamine-type stimulants by LC-MS/MS.

Authors:  Robert A Middleberg; Joseph Homan
Journal:  Methods Mol Biol       Date:  2012

5.  Gas chromatography-ion trap mass spectrometry method for the simultaneous measurement of MDMA (ecstasy) and its metabolites, MDA, HMA, and HMMA in plasma and urine.

Authors:  Daniel Gomes da Silva; Paula Guedes de Pinho; Helena Pontes; Luísa Ferreira; Paula Branco; Fernando Remião; Félix Carvalho; M Lurdes Bastos; Helena Carmo
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-02-04       Impact factor: 3.205

6.  Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics.

Authors:  M Farré; R de la Torre; B O Mathúna; P N Roset; A M Peiró; M Torrens; J Ortuño; M Pujadas; J Camí
Journal:  Psychopharmacology (Berl)       Date:  2004-04-08       Impact factor: 4.530

7.  Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration.

Authors:  Nathalie A Desrosiers; Allan J Barnes; Rebecca L Hartman; Karl B Scheidweiler; Erin A Kolbrich-Spargo; David A Gorelick; Robert S Goodwin; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-03-08       Impact factor: 4.142

8.  Determination of 19 drugs of abuse and metabolites in whole blood by high-performance liquid chromatography-tandem mass spectrometry.

Authors:  Marie Kjaergaard Bjørk; Marie K K Nielsen; Lotte Ø Markussen; Helene B Klinke; Kristian Linnet
Journal:  Anal Bioanal Chem       Date:  2009-11-18       Impact factor: 4.142

9.  Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration.

Authors:  Erin A Kolbrich; Robert S Goodwin; David A Gorelick; Robert J Hayes; Elliot A Stein; Marilyn A Huestis
Journal:  J Clin Psychopharmacol       Date:  2008-08       Impact factor: 3.153

10.  A validated gas chromatographic-electron impact ionization mass spectrometric method for methamphetamine, methylenedioxymethamphetamine (MDMA), and metabolites in mouse plasma and brain.

Authors:  Karl B Scheidweiler; Allan J Barnes; Marilyn A Huestis
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-11-07       Impact factor: 3.205

View more
  3 in total

1.  Improving the quality of biomarker candidates in untargeted metabolomics via peak table-based alignment of comprehensive two-dimensional gas chromatography-mass spectrometry data.

Authors:  Heather D Bean; Jane E Hill; Jean-Marie D Dimandja
Journal:  J Chromatogr A       Date:  2015-03-07       Impact factor: 4.759

Review 2.  MDMA for the treatment of mood disorder: all talk no substance?

Authors:  Rachel Patel; Daniel Titheradge
Journal:  Ther Adv Psychopharmacol       Date:  2015-06

3.  Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects.

Authors:  Sebastien Anizan; Marta Concheiro; Kurt R Lehner; Mohammad O Bukhari; Masaki Suzuki; Kenner C Rice; Michael H Baumann; Marilyn A Huestis
Journal:  Addict Biol       Date:  2014-12-05       Impact factor: 4.280

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.